公开(公告)号：EP2704743A4

公开(公告)日：2014-11-05

申请号：EP12779347

申请日：2012-05-04

申请人： OMEROS CORP

发明人： DUDLER THOMAS ,  GOMBOTZ WAYNE R ,  PARENT JAMES BRIAN ,  TEDFORD CLARK E ,  KAVLIE ANITA ,  HAGEMANN URS BEAT ,  REIERSEN HERALD ,  KIPRIJANOV SERGEJ

IPC分类号： C07K16/40 ,  A61K39/395 ,  C12N1/19 ,  C12N5/10 ,  C12N15/13 ,  C12N15/63 ,  C12P21/08

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/6424 ,  C12Y304/21104

摘要： The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

摘要翻译： 本发明涉及抗MASP-2抑制性抗体和包含用于抑制MASP-2依赖性补体活化的不良作用的抗体的组合物。

公开(公告)号：EP3057993A4

公开(公告)日：2017-09-13

申请号：EP14853910

申请日：2014-10-17

申请人： OMEROS CORP ,  UNIV LEICESTER

发明人： DEMOPULOS GREGORY A ,  DUDLER THOMAS ,  SCHWAEBLE HANS-WILHELM

IPC分类号： C07K16/40

CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact.

摘要翻译： 一方面，本发明提供了抑制患有或有发生血栓性微血管病（TMA）风险的活体中MASP-2依赖性补体活化作用的方法。 该方法包括向有需要的受试者施用有效抑制MASP-2依赖性补体激活的量的MASP-2抑制剂的步骤。 在一些实施方案中，MASP-2抑制剂抑制与MASP-2介导的替代补体途径活化相关的细胞损伤，同时使免疫系统的经典（C1q依赖性）途径组分保持完整。

公开(公告)号：EP2861246A4

公开(公告)日：2016-03-23

申请号：EP13807326

申请日：2013-06-18

申请人： OMEROS CORP ,  UNIV LEICESTER

发明人： SCHWAEBLE HANS-WILHELM ,  DEMOPULOS GREGORY A ,  DUDLER THOMAS ,  GRAY PATRICK

IPC分类号： A61K39/00 ,  A61K45/06 ,  C07K16/18 ,  C07K16/40

CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.